Publication of clinical Phase Ib trial data for the adjuvanted RH5.1 blood-stage malaria vaccine
Hørsholm, Denmark, 21 June 2024 – ExpreS[2]ion Biotech Holding AB’s affiliate ExpreS[2]ion Biotechnologies ApS (“ExpreS2ion") announces the new publication in The Lancet of a scientific paper titled “Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trial”. The article is based on a clinical study conducted by researchers at the University of Oxford.Chief Scientific Officer Farshad Guirakhoo comments: “These are the first data on the RH5.1/Matrix-M blood-stage malaria